Irritable bowel syndrome drugs receive FDA approval

The FDA has granted approval to two drugs for the treatment of diarrhea-predominant irritable bowel syndrome in adults. Actavis’ eluxadoline reduces bowel contractions and constipation risk, while Valeant Pharmaceuticals’ rifaximin was previously approved as a treatment for traveler’s diarrhea. The approvals were backed by trial data showing the drugs improved IBS-D symptoms more effectively than placebo.

Sources